Short Report

A spleen tyrosine kinase inhibitor attenuates the proliferation and migration of vascular smooth muscle cells

Hyang-Hee Seo1, Sang Woo Kim2, Chang Youn Lee3, Kyu Hee Lim4, Jiyun Lee1, Eunhyun Choi2, Soyeon Lim2, Seahyoung Lee2* and Ki-Chul Hwang2*

Abstract

Background: Pathologic vascular smooth muscle cell (VSMC) proliferation and migration after vascular injury promotes the development of occlusive vascular disease. Therefore, an effective chemical agent to suppress aberrant proliferation and migration of VSMCs can be a potential therapeutic modality for occlusive vascular disease such as atherosclerosis and restenosis. To find an anti-proliferative chemical agent for VSMCs, we screened an in-house small molecule library, and the selected small molecule was further validated for its anti-proliferative effect on VSMCs using multiple approaches, such as cell proliferation assays, wound healing assays, transwell migration assays, and ex vivo aortic ring assay.

Results: Among 43 initially screened small molecule inhibitors of kinases that have no known anti-proliferative effect on VSMCs, a spleen tyrosine kinase (Syk) inhibitor (BAY61-3606) showed significant anti-proliferative effect on VSMCs. Further experiments indicated that BAY61 attenuated the VSMC proliferation in both concentration- and time-dependent manner, and it also significantly suppressed the migration of VSMCs as assessed by both wound healing assays and transwell assays. Additionally, BAY61 suppressed the sprouting of VSMCs from endothelium-removed aortic rings.

Conclusion: The present study identified a Syk kinase inhibitor as a potent VSMC proliferation and migration inhibitor and warrants further studies to elucidate its underlying molecular mechanisms, such as its primary target, and to validate its in vivo efficacy as a therapeutic agent for restenosis and atherosclerosis.

Keywords: Syk kinase inhibitor, BAY61-3606, VSMC, Proliferation, Migration

Background

Normal vascular smooth muscle cells (VSMCs) maintain a minimal proliferation rate and active contractility [1]. However, non-physiologic stimuli, such as excessive cytokines, shear stress, vascular injury, or inflammation, can promote the phenotypic switch of VSMCs from a contractile type to a synthetic phenotype [2, 3], leading to the development of occlusive vascular diseases [4, 5]. Such aberrant proliferation and migration of VSMCs limit the long-term efficacy of the clinical interventions such as angioplasty, stents, and coronary bypass [6]. To overcome this problem of excessive VSMC proliferation, advanced approaches (i.e., drug-eluting stents) have been tried and produced some promising results [7]. Nevertheless, the incidence of drug-eluding stent failure still remains at approximately 10%, [7, 8]. Furthermore, although different modalities, including calcium channel blockers, antiplatelet drugs, and angiotensin converting enzyme inhibitors, have been tried to control occlusive vascular disease, the results were not consistent [9]. Therefore, searching alternative means to control the aberrant proliferation and migration of VSMCs is still an...
important task for developing an optimized therapeutics to treat occlusive disease.

In the present study, we screened number of small molecule inhibitors of six major kinase subfamilies, to find an alternative therapeutic agent for suppressing VSMC proliferation and migration based on the results of multiple experiments, such as cell proliferation assays, wound healing assays, and transwell migration assays, that assessed the anti-proliferative and migratory effect on in vitro. The effect of the selected small molecule on the sprouting of VSMCs from endothelium-denuded aortic rings was also examined. The results indicated that the selected small molecule, a spleen tyrosine kinase (Syk) inhibitor (BAY61-3606), is an effective agent for suppressing proliferation and migration of VSMCs in vitro and ex vivo and that has therapeutic potential for treating occlusive vascular disease involving aberrant proliferation and migration of VSMCs.

Results

Initial screening of small molecules for anti-proliferative effect on VSMCs

For initial screening, through a literature search, 43 small molecules (Table 1), whose effects on VSMC proliferation and migration had not been reported, were selected from an in-house small molecule library mainly composed of commercially available inhibitors of six kinase subfamilies [10]. The effect of those 43 small molecules on VSMC proliferation was then examined. VSMCs were treated with each small molecule (10 μM) for 24 h, and cellular proliferation was determined by using a cell proliferation assay kit (CCK-8). The results indicated that the small molecule number 129 most significantly inhibited the proliferation of VSMCs, compared to the vehicle groups (DMSO 2%, v/v) (Fig. 1). The identity of compound 129 was BAY 61-3606 hydrochloride, a Syk inhibitor [11].

BAY61 inhibits VSMC proliferation in a concentration and time-dependent manner

To examine the concentration-dependent effect of the Syk inhibitor (BAY61), VSMCs were treated with increasing concentrations of BAY61 (1, 5, 10, and 20 μM) for 24 h. The cellular proliferation results indicated that BAY61 had a significant anti-proliferative effect at all concentrations tested, although the effect was more profound with concentrations of 5 μM or higher (Fig. 2a, b). At the concentration of 10 μM, BAY61 showed a significant anti-proliferative effect without any prominent morphological changes. On the other hand, at a concentration of 20 μM, the cells started to detach from the culture plate and to clump together. Therefore, for further experiments, 10 μM was used to examine the anti-proliferative effects of BAY61. To further examine the time-dependent effect of BAY61, VSMCs were treated with 10 μM of BAY61 for up to 48 h, and the cellular proliferation was decreased by BAY61 in a time-dependent manner (Fig. 2c).

Table 1 List of small molecules used for initial screening

| D2  | p-Aminoclonidine hydrochloride |
| D3  | Isoetharine mesylate salt      |
| D6  | N6-2-(4-aminophenyl) ethyladenosine |
| D7  | ABT-702 dihydrochloride        |
| D9  | 9-Cyclopentyladenine monomethansulfonate |
| D14 | (−)-p-Bromolevamisole oxalate |
| D23 | TBBz                           |
| D24 | A3 hydrochloride               |
| D29 | Kenpaullone                    |
| D35 | TG003                          |
| D42 | DMNB (4,5-dimethoxy-2-nitrobenzaldehyde) |
| D43 | R(+)-Bromo-APB hydrobromide    |
| D44 | S-(−)-Eticlopride hydrochloride |
| D45 | BP897                          |
| D46 | GW2974                         |
| D50 | SCH-202676 hydrobromide        |
| D58 | I-OMe-Tyrphostin AG 538       |
| D59 | IRAK-1/4 inhibitor-1           |
| D60 | ZM 39923 hydrochloride         |
| D64 | Pinacilid monohydrate          |
| D66 | NS 8593 hydrochloride          |
| D68 | PD 98059                       |
| D74 | CGP 57380                      |
| D75 | Triamterene                    |
| D78 | Aminolide hydrochloride hydrate |
| D80 | Prilocaine hydrochloride       |
| D85 | N-p-Tosyl-l-phenylalanine chloromethyl ketone |
| D87 | N-(3,3-Diphenylpropyl)glycinamide |
| D88 | JX401                          |
| D89 | SD-169                         |
| D94 | Enoximone, >99% HPLC           |
| D95 | 4-(3-Butoxy-4-methoxybenzyl)imidazolidin-2-one |
| D97 | YM 976                         |
| D101| AS604850                       |
| D104| 7,8-Dihydroxycoumarin          |
| D105| 8-(4-Chlorophenylthio) adenosine 3’,5’-cyclic monophosphate sodium salt |
| D110| Hipsidin                       |
| D119| BTO-1                          |
| D129| BAY 61-3606 hydrochloride      |
| D134| Tyrphostin AG879               |
| D135| SU4321                         |
| D143| Tetracaine hydrochloride       |
| D144| Vanillic acid diethylamide     |
To evaluate the anti-migratory effect of BAY61, wound healing assays and transwell migration assays were conducted. According to the data, when the cells were stimulated with 10% FBS, the scratching wound produced with a yellow pipet tip was approximately 90% closed at 24 h, but the wound treated with BAY61 (10 μM) remained about 50% unclosed (Fig. 3a). Furthermore, BAY61 apparently decreased the number of cells that migrated through the transwell even in the presence of 10% serum (Fig. 3b).

BAY61 suppresses VSMC sprouting from aortic rings ex vivo

To further investigate the effect of BAY61 on VSMC proliferation, an ex vivo aortic ring assay was performed. The endothelium-denuded thoracic aortas of rats were cut to prepare aortic rings with thickness of 1 mm. Matrigel-embedded aortic rings were cultured in 10% FBS-supplemented DMEM with either vehicle (DMSO 2%, v/v) or BAY61 (10 μM) for 7 days. VSMC sprouting from the endothelium-denuded aortic rings was inhibited by BAY61 even in the presence of 10% FBS in the culture medium (Fig. 4).

Discussion

In the present study, through a screening of small molecule inhibitors of kinase subfamilies, we identified a Syk inhibitor as a potent anti-proliferative and migratory small molecule for VSMCs. Protein kinases are known to play critical roles in signaling pathways implicated in development, differentiation, death and proliferation of cells [12]. Therefore, it is reasonable to hypothesize that a certain kinase inhibitor can suppress proliferation and migration of VSMCs. Regarding the effect of BAY61 on cellular proliferation and migration, it has been reported that BAY61 significantly reduced the proliferation and migration of multiple myeloma cells [13] and it prevented airway epithelial cell proliferation and migration [14]. However, to our best knowledge, no previous study had reported anti-proliferative and migratory effects of this particular small molecule on VSMCs. Therefore, the present study is the first study to examine the effect of BAY61 on VSMC proliferation and migration.

Syk, along with zeta-chain associated kinase of 70 kDa (Zap-70), is a member of the Syk family of kinases that are activated downstream of Src kinases [15]. Syk is known to be mainly expressed in hematopoietic cells, but its expression has been also reported in epithelial cells and endothelial cells [16, 17]. The reported roles of Syk include, but not limited to, relaying adaptive immune receptor signaling, cellular adhesion, innate immune recognition, platelet activation, and vascular development [18]. Pertaining to the role of Syk in VSMC proliferation, it has been reported that inhibition or knockdown of Syk significantly prevented platelet-derived growth factor (PDGF)-induced proliferation and migration [19].

Our data also clearly demonstrated that the Syk inhibitor BAY61 significantly suppressed VSMC proliferation and migration. Previous study had reported that suppression of Syk activation led to subsequent inhibition of extracellular signal-regulated kinases (ERK) 1/2 signaling and p38 mitogen-activated protein kinase signaling [20]. Therefore, it is highly possible that BAY61 also inhibited VSMC proliferation and migration via suppression of ERK and p38 pathways. Although we did not examined detailed mechanisms of BAY61 and it is a major limitation of the present study, we are currently conducting a further study evaluating the in vivo efficacy of BAY61 in comparison to other well-known SMC proliferation inhibitor such as paclitaxel and the underlying mechanism of BAY61 will be also examined in detail.

Our ex vivo aortic ring assay result showed that BAY61 prevented sprouting of VSMCs, and furthermore, suppression of Syk has been suggested to be an effective way to control atherosclerosis via subsequent suppression of endothelin-1 production from...
endothelial cells [21]. Therefore, BAY61 is a strong candidate for an effective therapeutic agent targeting occlusive vascular diseases, such as restenosis, and it deserves further investigation to prove its in vivo efficacy and safety.

**Conclusions**

In summary, as an effort to identify anti-proliferative agent to control occlusive vascular disease, this paper describes the anti-proliferative and migratory effects of BAY61, a Syk inhibitor, on VSMCs for the first time. The
selected Syk inhibitor significantly suppressed VSMC proliferation and migration in vitro and ex vivo. These data suggest that the BAY61 may be a potent therapeutic agent for the treatment of occlusive vascular disease and warrants further studies to evaluate its in vivo efficacy and detailed underlying mechanism.

### Methods

**Isolation and culture of rat aortic VSMCs**

All experimental procedures for animal studies were approved by the Committee for the Care and Use of Laboratory Animals, Yonsei University College of Medicine, and were performed in accordance with the Committee’s guidelines and regulations for animal care. Rat aortic VSMCs were isolated and cultured using methods previously published [22]. The thoracic aortas from 6- to 8-week-old Sprague–Dawley rats were removed and transferred to serum-free Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, USA) containing 100 units/ml penicillin and 100 mg/ml streptomycin. The connective tissues were removed, and the aorta was transferred to a petri dish containing 5 ml of an enzyme dissociation mixture containing DMEM with 1 mg/ml collagenase type I (Sigma, USA) and 0.5 mg/ml elastase (USB Bioscience, USA) and was incubated for 30 min at 37 °C. The adventitia was stripped with forceps under a microscope. The aorta was transferred to a plastic tube containing 5 ml enzyme dissociation mixture and incubated for 2 h at 37 °C. The suspension was centrifuged (1500 rpm for 10 min), and the pellet was re-suspended with 10% fetal bovine serum (FBS) containing DMEM with 100 IU/ml penicillin and 100 mg/ml streptomycin in 75 cm² flasks at 37 °C in a humidified atmosphere of 95% air and 5% CO₂ (Forma Scientific, USA).

**Primary screening of small molecules**

From an in-house small molecule library mainly composed of inhibitors of six major kinase subfamilies, 43 candidate small molecules with no known anti-proliferative effects on VSMCs were selected based on a published literature search using Pubmed (http://www.ncbi.nlm.nih.gov/pubmed). For primary screening, VSMCs were seeded in 48-well culture plates using DMEM with 10% FBS and then treated with 10 μM of each candidate compound for 24 h. The anti-proliferative effects of the candidate compounds were determined by a cell proliferation assay.
Cell proliferation assay (cell counting kit 8, CCK 8)
To determine cell proliferation, cell proliferation assay using a WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt] solution (CCK-8, Dojindo, Japan) was conducted following protocol previously published [23]. Briefly, WST-8 solution was added to each well [10% (v/v)] and incubated at 37 °C for 2 h to allow for the formation of WST-8 formazan. The absorbance of a water soluble formazan dye was measured at 450 nm using a microplate reader (Molecular Devices, USA).

Wound healing assay
Wound healing assay, also as known as in vitro scratch assay, was conducted according to the protocol previously published [24]. VSMCs were plated at a density of 8 × 10^4 cells/well in six-well plates. After the cells had reached 90% confluence, wounds were produced by scratching with 200 μl pipette tips. The leading edge of the wounds was marked as a baseline. The medium was replaced with or without the chemical compound, and the cells were incubated for up to 48 h. Images were captured using an Axiovert 40C inverted microscope (Carl Zeiss, Germany) equipped with a Powershot A640 digital camera (Canon, Japan). The percent area remained unclosed (area between the leading edges at a given time point/area between the leading edges at baseline × 100) was measured.

Transwell migration assay
Transwell migration assay was performed according to the protocol previously published [25]. VSMCs (8 × 10^3 cells) were seeded onto the upper chamber of a transwell filter with 8 μm pores (Costar Corning, USA). The cells were deprived of serum for 24 h, and a candidate chemical compound was added to the lower chamber. Transwell chambers were incubated at 37 °C for 24 h. After incubation, the cells that migrated through the pores of the filter were stained with 0.25% crystal violet. Non-migrating cells on the upper side of the filter were removed with cotton swabs.

Western Blot analysis
VSMCs cultured in 60-mm dishes were treated with or without the selected chemical compound. Proteins were separated in a 10% SDS–polyacrylamide gel and transferred to PVDF membranes (Millipore, USA). After blocking the membrane with TBS-T (TBS-tween 20, 0.1% tween 20) containing 5% (w/v) non-fat dried skimmed milk powder for 1 h at room temperature, the membranes were washed twice with TBS-T and incubated with primary antibodies for 1 h at room temperature or overnight at 4 °C. The membranes were washed three times with TBS-T for 5 min and incubated with horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at room temperature. After extensive washing, the bands were detected using enhanced...
chemiluminescence (ECL®) reagent (AbClon, Republic of Korea). The band intensities were detected using a Photo-Image System (Molecular Dynamics, Canada). The primary antibodies were from Cell Signaling (cyclin D1:2978, p-ERK:9101, ERK:9102, p-Akt:9271, Akt:9272, Santa Cruz [PCNA (proliferating cell nuclear antigen):sc-56, p-Rb:sc-16670-R, Rb:sc-50], and Abcam (β-actin:ab8227).

**Ex vivo aortic ring assay**

Aortic ring assay to monitor the outgrowth of VSMCs was conducted following a published protocol with modifications [26]. Briefly, the thoracic aortas from 6- to 8-week-old Sprague–Dawley rats were removed and transferred to serum-free DMEM. The lining endothelium was denuded using a 2-Fr Fogarty balloon catheter (Baxter, USA) to minimize the possibility of endothelial cell sprouting during the ring assay. The aortas were washed by gradually passing through PBS three times. After removing perivascular adipose tissue, each aorta was cut into segments of aortic rings 1 mm in length that were placed in Matrigel (BD Biosciences, USA). The aortic rings were incubated with or without the selected chemical compound. Over the next 7 days, the aorta rings were monitored daily for the sprouting of VSMCs using a microscope.

**Statistical analysis**

Quantitative data were expressed as the mean ± SEM (standard error of measurement). For statistical analysis, one-way ANOVA with Bonferroni correction was performed using OriginPro 8 SR4 software (ver. 8.0951, OriginLab Corporation, USA) if there were more than three groups. A p value of less than 0.05 was considered statistically significant.

**Authors’ contributions**

HS participated in the study design, carried out cell culture including cell preparation, and revised the manuscript. SK drafted the manuscript and revised the manuscript. KH conceived the study, drafted the manuscript, and revised the manuscript. CL, KL, and JL participated in cell preparation, and revised the manuscript. SK drafted the manuscript and revised the manuscript. HS participated in the study design, carried out cell culture including cell culture. All authors read and approved the final manuscript.

**Author details**

1 Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, South Korea. 2 Institute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si, Gangwon-do, South Korea. 3 Department of Integrated Omics for Biomedical Sciences, Yonsei University, Seoul, South Korea. 4 Department of Veterinary Physiology, College of Veterinary Medicine, Chonbuk National University, Jeonju, Jeollabuk-do, South Korea.

**Acknowledgements**

This study was supported by grants funded by the Korea Ministry of Science, ICT and Future Planning (NRF-2015M3A9E6029519, and NFR-2015M3A9E6029407).

**Competing interests**

The authors declare that they have no competing interests.

**Received: 19 September 2016 Accepted: 9 December 2016 Published online: 18 January 2017**

**References**

1. Rensen SS, Doevendans PA, van Eys GJ. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J. 2007;15(3):100–8.
2. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res. 2012;95(2):156–64.
3. Louis SF, Zahradka P. Vascular smooth muscle cell motility: from migration to invasion. Exp Clin Cardiol. 2010;15(4):e75–85.
4. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84(3):767–801.
5. Rzucidlo EM, Martin KA, Powell RJ. Regulation of vascular smooth muscle cell differentiation. J Vasc Surg. 2007;45(Suppl A):A25–32.
6. Clowes AW, Redy MA. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia—a review. J Vasc Surg. 1991;13(6):885–91.
7. Farooq V, Gogas BD, Serruys PW. Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv. 2011;4(2):195–205.
8. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol. 2010;56(10 Suppl):S1–42.
9. Schomig A, Kastrati A, Wessely R. Prevention of restenosis by systemic drug therapy: back to the future? Circulation. 2005;112(18):2759–61.
10. Hwang KC, Kim JY, Chang W, Kim DS, Lim S, Kang SM, et al. Chemicals that modulate stem cell differentiation. Proc Natl Acad Sci USA. 2008;105(21):7467–71.
11. Yamamoto N, Takehiga K, Shichijo M, Kubo K, Tato M, Nakashima K, et al. The orally available spleen tyrosine kinase inhibitor 2-[(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther. 2003;306(3):1174–81.
12. Bononi A, Agnoletto C, De Marchi E, Marchi S, Paternagni S, Bonora M, et al. Protein kinases and phosphatases in the control of cell fate. Enzyme Res. 2011;2011:329098.
13. Koerber RM, Held SA, Heine A, Kothoff P, Daeeck S, Bringmann A, et al. Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma. Exp Hematol Oncol. 2015;4:21.
14. Wang X, Mychajliwcz M, Lau C, Gutierrez C, Scott JA, Chow CW. Spleen tyrosine kinase mediates BEAS-2B cell migration and proliferation and human rhinovirus-induced expression of vascular endothelial growth factor and interleukin-8. J Pharmacol Exp Ther. 2012;340(2):277–85.
15. Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal. 2010;22(8):1175–84.
16. Kurotsuki T. Functional dissection of BCR signaling pathways. Curr Opin Immunol. 2000;12(3):276–81.
17. Inatome R, Yanoji S, Takano T, Yamamura H. A critical role for Syk in endothelial cell proliferation and migration. Biochem Biophys Res Commun. 2001;286(1):195–9.
18. Mosca A, Ruland J, Tybulewicz VL. The Syk tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387–402.
19. Gao Z, Cao L, Luo Q, Wang X, Yu L, Wang T, et al. Spleen tyrosine kinase modulates the proliferation and phenotypes of vascular smooth muscle cells induced by platelet-derived growth factor. DNA Cell Biol. 2011;30(3):149–55.
20. Lee CK, Lee HM, Kim HJ, Park HJ, Won KJ, Roh HY, et al. Syk contributes to PDGF-BB-mediated migration of rat aortic smooth muscle cells via MAPK pathways. Cardiovasc Res. 2007;74(1):159–68.
21. Kim YJ, Koo TY, Yang WS, Han NJ, Jeong JU, Lee SK, et al. Activation of spleen tyrosine kinase is required for TNF-alpha-induced endothelin-1 upregulation in human aortic endothelial cells. FEBS Lett. 2012;586(6):818–26.
22. Kim MH, Ham O, Lee SY, Choi E, Lee CY, Park JH, et al. MicroRNA-365 inhibits the proliferation of vascular smooth muscle cells by targeting cyclin D1. J Cell Biochem. 2014;115(10):1752–61.

23. Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y, Ueno K. A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta. 1997;44(7):1299–305.

24. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2(2):329–33.

25. Marshall J. Transwell(R) invasion assays. Methods Mol Biol. 2011;769:97–110.

26. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D’Amico G, et al. Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc. 2011;7(1):89–104.